{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:34:31Z","timestamp":1779892471169,"version":"3.53.1"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2014,5,5]],"date-time":"2014-05-05T00:00:00Z","timestamp":1399248000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0096481","type":"journal-article","created":{"date-parts":[[2014,5,6]],"date-time":"2014-05-06T00:52:29Z","timestamp":1399337549000},"page":"e96481","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":32,"title":["Pharmacokinetics and Efficacy of Topically Applied Nonsteroidal Anti-Inflammatory Drugs in Retinochoroidal Tissues in Rabbits"],"prefix":"10.1371","volume":"9","author":[{"given":"Tetsuo","family":"Kida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiko","family":"Kozai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuyoshi","family":"Isaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Tokushige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,5,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1076\/opep.11.2.67.28158","article-title":"2002 global update of available data on visual impairment: a compilation of population-based prevalence studies","volume":"11","author":"D Pascolini","year":"2004","journal-title":"Ophthalmic Epidemiol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States","volume":"122","author":"N Congdon","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archopht.122.4.564","article-title":"Prevalence of age-related macular degeneration in the United States","volume":"122","author":"DS Friedman","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ophtha.2012.07.038","article-title":"Vascular endothelial growth factor A in intraocular vascular disease","volume":"120","author":"JW Miller","year":"2013","journal-title":"Ophthalmology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.ophtha.2013.01.058","article-title":"Implications of the comparisons of age-related macular degeneration treatments trials on clinical practice: what have we learned?","volume":"120","author":"DV Do","year":"2013","journal-title":"Ophthalmology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1517\/14656566.2013.787410","article-title":"An update on the pharmacotherapy of neovascular age-related macular degeneration","volume":"14","author":"KB Freund","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3109\/08820538.2011.570849","article-title":"Inflammation and age-related macular degeneration (AMD)","volume":"26","author":"DG Telander","year":"2011","journal-title":"Semin Ophthalmol"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Polansky J, Weinreb R (1984) Steroids as anti-inflammatory agent. In: Sears M, editor. Pharmacology of the Eye. New York: Springer. pp. 460\u2013583.","DOI":"10.1007\/978-3-642-69222-2_11"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archopht.1996.01100140208016","article-title":"Corticosteroid therapy of eye diseases. Fifty years later","volume":"114","author":"M Raizman","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/jop.1987.3.43","article-title":"Effects of steroidal and non-steroidal anti-inflammatory agents on corneal wound healing","volume":"3","author":"L Waterbury","year":"1987","journal-title":"J Ocul Pharmacol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000068563","article-title":"Topical nonsteroidal anti-inflammatory therapy in ophthalmology","volume":"217","author":"R Schalnus","year":"2003","journal-title":"Ophthalmologica"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.ophtha.2006.12.029","article-title":"Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation","volume":"114","year":"2007","journal-title":"Ophthalmology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000099294","article-title":"Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis","volume":"221","author":"E Uchio","year":"2007","journal-title":"Ophthalmologica"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1089\/jop.2011.0120","article-title":"Ocular pharmacokinetics profile of different indomethacin topical formulations","volume":"27","author":"C Bucolo","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1517\/14656560903188425","article-title":"Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent","volume":"10","author":"J Jones","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/OPTH.S4806","article-title":"Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution","volume":"3","author":"H Cho","year":"2009","journal-title":"Clin Ophthalmol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/labinvest.2011.101","article-title":"NSAIDs inhibit neovascularization of choroid through HO-1-dependent pathway","volume":"91","author":"N Yoshinaga","year":"2011","journal-title":"Lab Invest"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1097\/IAE.0b013e31825be87f","article-title":"Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration","volume":"32","author":"F Gomi","year":"2012","journal-title":"Retina"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1089\/jop.2007.0132","article-title":"Ocular pharmacokinetics of a single dose of bromfenac sodium ophthalmic solution 0.1% in human aqueous humor","volume":"24","author":"K Miyake","year":"2008","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1089\/jop.2007.0082","article-title":"24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits","volume":"24","author":"GA Baklayan","year":"2008","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0022-3565(24)34934-1","article-title":"Rofecoxib [Vioxx, MK-0966; 4-(4\u2032-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles","volume":"290","author":"CC Chan","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1023\/A:1026024409826","article-title":"Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac","volume":"27","author":"MA Kapin","year":"2003","journal-title":"Inflammation"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jcrs.2007.05.015","article-title":"In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac","volume":"33","author":"T Walters","year":"2007","journal-title":"J Cataract Refract Surg"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1023\/A:1007049015148","article-title":"Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy","volume":"24","author":"DA Gamache","year":"2000","journal-title":"Inflammation"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1021\/jm00377a001","article-title":"Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenyl acetic acid and analogues","volume":"11","author":"DA Walsh","year":"1984","journal-title":"J Med Chem"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.survophthal.2009.07.005","article-title":"Nonsteroidal anti-inflammatory drugs in ophthalmology","volume":"55","author":"SJ Kim","year":"2010","journal-title":"Surv Ophthalmol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF00126444","article-title":"QSAR and conformational analysis of the antiinflammatory agent amfenac and analogues","volume":"7","author":"J Ruiz","year":"1993","journal-title":"J Comput Aided Mol Des"},{"key":"ref28","first-page":"406","article-title":"Effects of bromfenac sodium, non-steroidal anti-inflammatory drug, on acute ocular inflammation","volume":"99","author":"T Ogawa","year":"1995","journal-title":"Nihon Ganka Gakkai Zasshi"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1185\/030079906X112471","article-title":"Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium","volume":"22","author":"LD Waterbury","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Chastain JE (2003) General considerations in ocular drug delivery. In: Mitra AK, editor. Ophthalmic Drug Delivery Systems, Second edition, Revised and Expanded. New York: Marcel Dekker Inc. pp. 59\u2013108.","DOI":"10.1201\/9780203912072.ch3"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/jps.2600670614","article-title":"Relationship between steroid permeability across excised rabbit cornea and octanol-water partition coefficients","volume":"67","author":"RD Schoenwald","year":"1978","journal-title":"J Pharm Sci"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0022-3565(25)38459-4","article-title":"Skin permeability and local tissue concentrations of nonsteroidal anti-inflammatory drugs after topical application","volume":"268","author":"P Singh","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1208\/s12248-008-9024-9","article-title":"Topical ocular delivery of NSAIDs","volume":"10","author":"M Ahuja","year":"2008","journal-title":"AAPS J"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1023\/A:1007001131987","article-title":"Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers","volume":"24","author":"TL Ke","year":"2000","journal-title":"Inflammation"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2133\/dmpk.14.32","article-title":"Ocular tissue distribution in rabbit after instillation of bromfenac sodium ophthalmic solution","volume":"14","author":"M Isaka","year":"1999","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1167\/iovs.02-0482","article-title":"Iganidipine, a new water-soluble Ca<sup>2+<\/sup> antagonist: ocular and periocular penetration after instillation","volume":"44","author":"K Ishii","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1167\/iovs.08-2922","article-title":"Route of penetration of topically instilled nipradilol into the ipsilateral posterior retina","volume":"50","author":"K Mizuno","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1755-3768.2008.01433.x","article-title":"Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery","volume":"87","author":"M Miyanaga","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jcrs.2007.07.017","article-title":"Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial","volume":"33","author":"HV Duong","year":"2007","journal-title":"J Cataract Refract Surg"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/jop.2011.0133","article-title":"A comparison of preservative-free diclofenac and preserved diclofenac eye drops after cataract surgery in patients with diabetic retinopathy","volume":"28","author":"K Yasuda","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Bucolo C, Marrazzo G, Platania CB, Romano GL, Drago F, et al. (2014) Effects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammation. J Pharm Pharmacol: doi: 10.1111\/jphp.12224.","DOI":"10.1111\/jphp.12224"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/IAE.0b013e318229b0af","article-title":"Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot study","volume":"32","author":"C Flaxel","year":"2012","journal-title":"Retina"},{"key":"ref43","first-page":"3483","article-title":"Concanavalin A-induced posterior subcapsular cataract: a new model of cataractogenesis","volume":"34","author":"A Gwon","year":"1993","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/DDDT.S39453","article-title":"Impact of ghrelin on vitreous cytokine levels in an experimental uveitis model","volume":"7","author":"B Turgut","year":"2013","journal-title":"Drug Des Devel Ther"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0096481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T20:12:25Z","timestamp":1746216745000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0096481"}},"subtitle":[],"editor":[{"given":"Alfred S.","family":"Lewin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,5,5]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0096481","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,5]]}}}